X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES IPCA LABS VENUS REMEDIES/
IPCA LABS
 
P/E (TTM) x -883.5 27.8 - View Chart
P/BV x 0.3 2.1 12.1% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   IPCA LABS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
IPCA LABS
Mar-17
VENUS REMEDIES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs218643 33.9%   
Low Rs82503 16.3%   
Sales per share (Unadj.) Rs365.6254.4 143.7%  
Earnings per share (Unadj.) Rs1.516.1 9.2%  
Cash flow per share (Unadj.) Rs37.929.8 127.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs382.5194.6 196.6%  
Shares outstanding (eoy) m11.44126.20 9.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.3 18.2%   
Avg P/E ratio x101.035.7 283.2%  
P/CF ratio (eoy) x4.019.2 20.6%  
Price / Book Value ratio x0.42.9 13.3%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m1,71772,300 2.4%   
No. of employees `0001.013.3 7.7%   
Total wages/salary Rs m3246,960 4.7%   
Avg. sales/employee Rs Th4,100.72,413.5 169.9%   
Avg. wages/employee Rs Th318.0523.2 60.8%   
Avg. net profit/employee Rs Th16.7152.4 10.9%   
INCOME DATA
Net Sales Rs m4,18332,106 13.0%  
Other income Rs m20226 8.9%   
Total revenues Rs m4,20332,332 13.0%   
Gross profit Rs m8124,448 18.2%  
Depreciation Rs m4171,730 24.1%   
Interest Rs m380241 157.7%   
Profit before tax Rs m352,703 1.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m18675 2.7%   
Profit after tax Rs m172,028 0.8%  
Gross profit margin %19.413.9 140.1%  
Effective tax rate %51.625.0 206.5%   
Net profit margin %0.46.3 6.4%  
BALANCE SHEET DATA
Current assets Rs m2,77117,340 16.0%   
Current liabilities Rs m1,9319,559 20.2%   
Net working cap to sales %20.124.2 82.8%  
Current ratio x1.41.8 79.1%  
Inventory Days Days125100 124.7%  
Debtors Days Days5457 94.5%  
Net fixed assets Rs m5,32820,779 25.6%   
Share capital Rs m114252 45.3%   
"Free" reserves Rs m4,17724,499 17.1%   
Net worth Rs m4,37624,553 17.8%   
Long term debt Rs m1,9113,517 54.3%   
Total assets Rs m8,42839,595 21.3%  
Interest coverage x1.112.2 8.9%   
Debt to equity ratio x0.40.1 304.7%  
Sales to assets ratio x0.50.8 61.2%   
Return on assets %4.75.7 82.2%  
Return on equity %0.48.3 4.7%  
Return on capital %6.610.5 62.9%  
Exports to sales %048.6 0.0%   
Imports to sales %20.514.2 144.1%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs m8584,571 18.8%   
Fx inflow Rs m015,617 0.0%   
Fx outflow Rs m8585,828 14.7%   
Net fx Rs m-8589,790 -8.8%   
CASH FLOW
From Operations Rs m4692,764 17.0%  
From Investments Rs m29-1,432 -2.0%  
From Financial Activity Rs m-464-1,591 29.1%  
Net Cashflow Rs m35-259 -13.3%  

Share Holding

Indian Promoters % 32.9 45.9 71.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.4 1.6%  
FIIs % 0.6 25.3 2.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.4 381.6%  
Shareholders   20,121 36,892 54.5%  
Pledged promoter(s) holding % 36.4 2.1 1,699.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   UNICHEM LAB  SUN PHARMA  PFIZER  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Lupin up 4%(01:30 pm)

After opening the day flat, share markets in India remained rangebound and are presently trading marginally above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 24, 2017 02:37 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - GSK PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS